Hypoallergenic Claim Assessment
What is Hypoallergenic Claim Assessment?
A qualified review of low-allergy-potential evidence, not a no-allergy guarantee.
Why do you need this service?
Use hypoallergenic claim assessment to review formulation, exposure and evidence relevant to low allergy potential. The assessment supports qualified wording for the intended product and users, without promising that nobody will react.
Be the first company on this service page
No published company profiles are linked to Hypoallergenic Claim Assessment or its more specific services yet. Explore the service categories or add an explicitly supported capability to your company profile.
Hypoallergenicity
Hypoallergenicity is a safety and claim-support question, not a preclinical efficacy benefit. Assessment considers the formulation, ingredient hazards, exposure, and relevant test evidence. A negative result in one assay does not establish that a finished product is non-allergenic.
Sensitization-related methods
Different methods address steps in the skin-sensitization process. DPRA measures reactivity with model peptides, not binding to actual skin in a user. KeratinoSens assesses a cellular stress-response pathway associated with sensitization, while h-CLAT measures immune-cell activation markers. Other approaches, such as U937-based methods, must be judged for their intended applicability.
- Selection of methods suitable for the ingredient or mixture
- Review of method limitations and possible interference
- Interpretation across complementary evidence
- Identification of ingredients or exposures needing further assessment
Irritation is a separate endpoint
Reconstructed epidermis models, including suitable EpiSkin or SkinEthic systems, can assess irritation through protocol-specific measurements such as tissue viability. Inflammatory mediators and barrier measurements may add context, but low irritation does not demonstrate low sensitization potential.
The final rationale must support the intended wording and target market requirements. Further human evidence may be relevant, but human patch testing is not a universal next step and cannot exclude reactions in all future users.
Preparing a hypoallergenic claim assessment
Provide the complete formula, ingredient information, intended use and the exact claim under consideration. Existing sensitization data and documented reactions help identify what the evidence covers and where uncertainty remains. Irritation and allergy are different endpoints and should remain separate in the review.
Further testing should address a defined evidence gap and the applicability of the available methods. Human patch or repeated-insult studies are clinical investigations and need prior safety justification; they are not a default substitute for hazard assessment.
The conclusion should connect the wording to the reviewed formula, exposure and population. It cannot establish zero allergy risk, faster FDA approval or universal market acceptance. A subsequent formula change may require the evidence and claim to be reconsidered.
Find cosmetic safety services covering laboratory hazards, human tolerance, exposure-based assessment and evidence needed for specific tolerance claims. Explore another Cosmetic Safety Testing page on cosmetic-labs.com.